₹1,573.50
−2.35%NSE close, 16 Nov 2026
+43.35%
Symbiotec Pharmalab is a small cap company, listed on NSE under the symbol SYMBIOTEC. At ₹1,573.50 a share, the market values the whole company at ₹10,111 crore.
Promoters hold 33.28% of the shares, and have pledged 38.5% of their holding. Foreign institutions hold 3.79%, and domestic institutions, mutual funds among them, 33.17%.
₹ crore. Consolidated figures.
Transcript
Schedule of meet
Link of Recording
General Updates ((Symbiotec Signs 10-Year Take-Or-Pay Agreement To Manufacture Fermentation-Based Alternative Protein For EU Innovator))
| Tax | 3.5 | 12.3 |
|---|
| Net profit | 14.1 | 51.7 |
|---|
| EPS (₹) | 2.24 | 8.20 |
|---|
₹ crore, financial years to March.
Not filed yet.
₹ crore, at each year's end and the latest half year.
| Line | Sep 2026 |
|---|---|
| Shareholders’ equity | 1,361 |
| Borrowings | 333 |
| Total liabilities | 683 |
| Fixed assets | 1,055 |
| Investments | 4.5 |
| Cash and equivalents | 21.7 |
| Total assets | 2,044 |
₹ crore, by financial year, and the latest half year.
| Line | 6M to Sep 2026 |
|---|---|
| From operations | 45.9 |
| From investing | −112 |
| From financing | 134 |
| Spent on fixed assets | −114 |
| Free cash flow | −67.6 |
Margins, returns, debt, tax and cash.
Not filed yet.
The Monitoring Agency Report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the Initial Public Offer (IPO) of the Company for the quarter year ended September 30, 2026
Investor Release being issued by the Company for the Quarter and half year ended September 30, 2026
The financial results for the period ended September 30, 2026.
Schedule of meet
Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement with a leading global pharmaceutical company forDual Chamber Vial ('DCV') products in the U.S.
Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report ("EIR") From U.S. FDA for Its Manufacturing Facility In Pithampur ('SEZ') With VAI Classification
Investor Release of Financial Results for the 1st Quarter ended June 30, 2026
Outcome of Board Meeting held on September 21, 2026.